Plasma NGAL levels were determined using stored EDTA-plasma by an in-house time resolved immunofluorometric (TRIFMA) sandwich-type assay based on anti-NGAL antibodies and recombinant NGAL from R&D Systems (Abingdon, UK).
The simulations are based on an in-house time-marching strategy incorporating Lagrange multipliers for the unilateral contact treatment, as well as centrifugal stiffening and abradable coating removal.
The investigation is conducted by extending to cyclically symmetric structures an in-house time-marching based tool dedicated to unilateral contact occurrences in turbomachines.
Plasma sC5b-9 wanalyzedzed using a novel, sensitive, in-house, time-resolved immunofluorometric assay (9).
NGAL was measured using a validated in-house Time-Resolved Immuno-flourometric assay (TRIFMA).
S-MBL levels were measured using an in-house, time-resolved immunofluorometric assay (12).
IGFBP-2 was determined by a validated in-house time-resolved immunofluorometric assay (TR-IFMA) as previously described [ 15].
IGFBP-1 was determined by an in-house time-resolved immunofluorometric assay (TR-IFMA) with slight modifications as recently described [ 14].
Serum adiponectin was measured by an in-house time-resolved immunofluorometric assay based on two antibodies and recombinant human adiponectin (R&D Systems, Abingdon, U.K ., as previously described (23).
As presented previously, the MBL concentration was measured using an in-house time-resolved immunofluorometric assay based on the recognition of a physiologically relevant ligand combined with detection by a specific monoclonal antibody (11).
Serum levels of immunoreactive (total) IGF-I (final dilution 1 1000) were determined in acid ethanol serum extracts using a validated, in-house time-resolved immunofluorometric assay (TR-IFMA) as previously described [ 34] with slight modifications: first, the IGF-I assay had been calibrated against the international IGF-I reference preparation WHO 02/254.
